Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of vedolizumab IV in steroid-refractory acute intestinal GvHD after allo-HSCT
2016-002985-30Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vedolizumab in graft-versus-host disease (GVHD), sponsored by Millennium Pharmaceuticals. Primary endpoint: Overall response at Day 28. Started Jan 2017; status: completed.
02
Drugs
vedolizumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2016-002985-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002985-30.